|
Name |
16-Desacetylfusidic acid
|
Molecular Formula | C29H46O5 | |
IUPAC Name* |
6-methyl-2-(3,11,16-trihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene)hept-5-enoicacid
|
|
SMILES |
CC(C)=CCCC(C(=O)O)=C1C(O)CC2(C)C1CC(O)C1C3(C)CCC(O)C(C)C3CCC12C
|
|
InChI |
InChI=1S/C29H46O5/c1-16(2)8-7-9-18(26(33)34)24-20-14-22(31)25-27(4)12-11-21(30)17(3)19(27)10-13-28(25,5)29(20,6)15-23(24)32/h8,17,19-23,25,30-32H,7,9-15H2,1-6H3,(H,33,34)/b24-18-/t17-,19-,20-,21+,22+,23-,25-,27-,28-,29-/m0/s1
|
|
InChIKey |
ZYPQPWJLUKNCQX-OHXMNYGTSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 474.68 | ALogp: | 5.1 |
HBD: | 4 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 98.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.322 |
Caco-2 Permeability: | -5.208 | MDCK Permeability: | 0.00002140 |
Pgp-inhibitor: | 0.038 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.615 | 20% Bioavailability (F20%): | 0.11 |
30% Bioavailability (F30%): | 0.501 |
Blood-Brain-Barrier Penetration (BBB): | 0.912 | Plasma Protein Binding (PPB): | 96.80% |
Volume Distribution (VD): | 0.664 | Fu: | 3.65% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.577 |
CYP2C19-inhibitor: | 0.006 | CYP2C19-substrate: | 0.921 |
CYP2C9-inhibitor: | 0.038 | CYP2C9-substrate: | 0.933 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.189 |
CYP3A4-inhibitor: | 0.055 | CYP3A4-substrate: | 0.073 |
Clearance (CL): | 23.552 | Half-life (T1/2): | 0.122 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.59 |
Drug-inuced Liver Injury (DILI): | 0.034 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.815 | Maximum Recommended Daily Dose: | 0.166 |
Skin Sensitization: | 0.043 | Carcinogencity: | 0.034 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.163 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001478 | 0.810 | D0X7XG | 0.810 | ||||
ENC005284 | 0.633 | D03ZTE | 0.333 | ||||
ENC002152 | 0.460 | D0G3SH | 0.333 | ||||
ENC003780 | 0.401 | D0OR2L | 0.328 | ||||
ENC005285 | 0.400 | D0M4WA | 0.321 | ||||
ENC002467 | 0.399 | D04SFH | 0.293 | ||||
ENC005155 | 0.397 | D0I2SD | 0.282 | ||||
ENC003848 | 0.390 | D00VZZ | 0.281 | ||||
ENC001918 | 0.370 | D0KR5B | 0.276 | ||||
ENC002246 | 0.361 | D08PIQ | 0.271 |